COMPOSITION OF PERIPHERAL BLOOD LEUKOCYTE SUBSETS IN RATS WITH DIFFERENT MODELS OF ALZHEIMER'S DISEASE
DOI: 10.17721/1728.2748.2023.94.28-34
Keywords:
Alzheimer's disease, leukocytes, inflammation, lymphocyces, monocytes, neutrophilsAbstract
Background. Systemic inflammation is recognized a sone of the key features of Alzheimer's disease (AD) – a neurodegenerative disorder, which is characterized by cognitive decline with progressive memory loss and affects millions of predominantlyeld erly people. Recent literature data suggest the involvement of periphera limmune cells in the initiation and progression of AD. However, our understanding of the population composition of peripheral blood leukocytes and its contribution to disease progression remains limited. The use of anima lmodels plays an important role in investigating possible mechanisms linking the periphera limmune system to the inflammatory processes underlying neurode generation. The aim of this study was comparative assessment of the composition of leukocyte subsets in rats with AD, induced by intrahippocampa linjection of amyloidbeta (Aβ) 1–40 and Aβ 25–35.
Methods. Male Wistar rats were used in the experiments, including intact and sham-operated animals as controls. Disease development was confirmed b y assessing cognitive impairment in the Barnesmaze be havioral test and by the loss of dopaminergic neurons. Hematological parameters were evaluatedat the end of the experiment (day 37 after the disease initiation), including absolute leukocyte count, as well as absolute and relative count of their main subsets: lymphocytes, monocytes, andneutrophils. Rats with AD induced by Aβ 1–40 exhibited granulocytosis (a fivefold increase in absolute granulocyte countin the circulation). Absolute and relative count of lymphocytes In these animals were decreased on average by 2.5 times, monocyte count – on average by 3 times as compared to those in intactand sham-operated rats.In rats with Αβ 25–35-induced AD, leukocytosis with slightly decreased lymphocyte proportion, increase in monocyte count twice at average and unchanged neutrophil countwere revealed.
Results. Therefore, animalswith AD, inducedby Aβ 1–40, had hematologic markers of systemic inflammation (leukocytosis, granulocytosis, lymphocytopenia, andmonocytopenia).
Conclusions. These results suggest that the Aβ 1–40-induced AD model more accurately reproduces the hematologic signs of systemic inflammation observed in patients with this pathology.
References
Alzheimer's disease facts and figures. (2023). Alzheimers & Dementia, 19(4), 1598–1695. https://doi.org/10.1002/alz.13016
Abbas, A. K., Lichtman, A. H., & Pillai, S. (2020). Cellular and Molecular Immunology E-Book. Elsevier Health Sciences.
Akhtar, A., Gupta, S.M., Dwivedi, S., Kumar, D., Shaikh, M.F., & Negi, A.S. (2022). Preclinical Models for Alzheimer's Disease: Past, Present, and Future Approaches. ACS Omega, 7(51), 47504–47517. https://doi.org/10.1021/acsomega.2c05609
Bennett, M.L., Bennett, F.C., Liddelow, S.A., Ajami, B., Zamanian, J.L., Fernhoff, N.B., Mulinyawe, S.B., Bohlen, C.J., Adil, A., Tucker, A.M., Weissman, I.L., Chang, E.Y., Li, G., Grant, G.A., Gephart, M.H., & Barres, B.A. (2016). New tools for studying microglia in the mouse and human CNS. Proceedings of the National Academy of Sciences of the United States of America, 113(12). https://doi.org/10.1073/pnas.1525528113
Butovsky, O., & Weiner, H.L. (2018). Microglial signatures and their role in health and disease. Nature Reviews Neuroscience, 19(10), 622–635. https://doi.org/10.1038/s41583-018-0057-5
D'Andrea, M.R. (2016). Intracellular Consequences of Amyloid in Alzheimer's Disease. Academic Press. Fricker, G., Ott, M., & Mahringer, A. (Eds.) (2014). The Blood Brain Barrier (BBB). In Topics in Medicinal Chemistry (TMC), 10, Springer.
Garfias, S.R., Domínguez, B.T., Rojas, A.T., Arroyo, M.P.M., Rodríguez, U., Boll, C., Sosa, A.L., Sciutto, E., Adalid-Peralta, L., López, Y.M., Fragoso, G., & Fleury, A. (2022). Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson's diseases. Neurología. https://doi.org/10.1016/j.nrleng.2018.10.022
Herrero-Cervera, A., Soehnlein, O., & Kenne, E. (2022). Neutrophils in chronic inflammatory diseases. Cellular & molecular immunology, 19(2), 177–191. https://doi.org/10.1038/s41423-021-00832-3
Huang, L., Zhang, C., Wang, Y., & Wang, J. (2022). Association of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.888946
Huang, L.T., Zhang, C.P., Wang, Y.B., & Wang. J.H. (2022). Association of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis. Frontiers Aging Neuroscience, 14, 888946. https://doi.org/10.3389/fnagi.2022.888946
Huang, X., Hussain, B., & Chang, J. (2021). Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. CNS Neuroscience & Therapeutics, 27(1), 36–47. https://doi.org/10.1111/cns.13569
Jia, R., Chen, Y., & Xu, Y. (2019). Effects of physical activity and exercise on the cognitive function of patients with Alzheimer disease: a meta-analysis. BMC Geriatrics, 19(1). https://doi.org/10.1186/s12877-019-1175-2
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D., Ormaechea, J.F., Thouvenot, E., Delaby, C., Hirtz, C., Vialaret, J., Ginestet, N., Bouaziz-Amar, E., Laplanche, J., Labauge, P., Paquet, C., Lleó, A., & Gabelle, A. (2020). Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research & Therapy, 12(1). https://doi.org/10.1186/s13195-020-00696-1
Maimaiti, A., Show, P.L., Minmin, W., Weiwei, M., Wenhui, S., Aikemu, A., & Maimaitiyiming, D. (2021). Improvement of Total Flavonoids from Dracocephalum moldavica L. in Rats with Chronic Mountain Sickness through 1H-NMR Metabonomics. Evidence-based Complementary and Alternative Medicine, 1–13. https://doi.org/10.1155/2021/6695346
Nefodova, A.M. Rudyk, M., Pasichnichenko M., Dovhyi R., Dovbynchuk, T., Tolstanova, G., Skivka, L. (2022). Pro-inflammatory effects of placebo neurosurgery in rats: age-related features. General Surgery, 2(3), 56–63. https://doi.org/10.30978/GS-2022-2-56
Perez, M.F., Bregonzio, C., Castro, M.G., & Saravia, F.E. (2022). Targeting Neuroinflammation in Central Nervous System Disorders: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers Media SA.
Saresella, M., Marventano, I., Piancone, F., La Rosa, F., Galimberti, D., Fenoglio, C., Scarpini, E., & Clerici, M. (2020). IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment. Journal of Neuroinflammation, 17(1). https://doi.org/10.1186/s12974-020-01806-4
Twarowski, B., & Herbet, M. (2023). Inflammatory Processes in Alzheimer's Disease–Pathomechanism, Diagnosis and Treatment: A Review. International Journal of Molecular Sciences, 24(7), 6518. https://doi.org/10.3390/ijms24076518
Unda, S.R., Antoniazzi, A.M., Altschul, D.J., & Marongiu, R. (2021). Peripheral Leukocytosis Predicts Cognitive Decline but not behavioral Disturbances: A Nationwide Study of Alzheimer's and Parkinson's Disease Patients. Dement Geriatr Cogn Disord, 50(2), 143–152. https://doi.org/10.1159/000516340
Villabona-Rueda, A., Erice, C., Pardo, C.A., & Stins, M.F. (2019). The Evolving Concept of the Blood Brain Barrier (BBB): from a Single Static Barrier to a Heterogeneous and Dynamic Relay Center. Frontiers in Cellular Neuroscience, 13. https://doi.org/10.3389/fncel.2019.00405
Wang, Y., Sun, Y., Luo, Y., Peng, D., Li, X., Yang, B., Wang, Q., & Kuang, H. (2021). Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.700587
Wu, T., Dejanovic, B., Gandham, V.D., Gogineni, A., Edmonds, R., Schauer, S.P., Srinivasan, K., Huntley, M. A., Wang, Y., Wang, T., Hedehus, M., Barck, K. H., Stark, M., Ngu, H., Foreman, O., Meilandt, W. J., Elstrott, J., Chang, M. C., Hansen, D. J., . . . Hanson, J. E. (2019). Complement C3 is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Reports, 28(8), 2111–2123.e6. https://doi.org/10.1016/j.celrep.2019.07.060
Xie, J., Van Hoecke, L., & Vandenbroucke, R.E. (2022). The Impact of Systemic Inflammation on Alzheimer's Disease Pathology. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.796867
Xie, L., Kang, H., Xu, Q., Chen, M.Z.Q., Liao, Y., Thiyagarajan, M., O'Donnell, J.S., Christensen, D.H., Nicholson, C., Iliff, J.J., Takano, T., & Deane, R. (2013). Sleep Drives Metabolite Clearance from the Adult Brain. Science, 342(6156), 373–377. https://doi.org/10.1126/science.1241224
Yokoyama, M., Kobayashi, H., Tatsumi, L. & Tomita, T. (2022). Mouse Models of Alzheimer's Disease. Front. Mol. Neurosci., 15, 912995. https://doi.org/10.3389/fnmol.2022.912995;
Zeiss C.J. (2015). Improving the predictive value of interventional animal models data. Drug. Discov. Today, 20(4), 475–482. https://doi.org/10.1016/j.drudis.2014.10.015
Zambrano, P., Suwalsky, M., Jemioła-Rzemińska, M., Gallardo-Nelson, M.J., Strzałka, K., & Muñoz-Torrero, D. (2021). Protective Role of a Donepezil-Huprine Hybrid against the β-Amyloid (1-42) Effect on Human Erythrocytes. International Journal of Molecular Sciences, 22(17), 9563. https://doi.org/10.3390/ijms22179563
